Investment Rating - The report maintains a "Buy" rating for the company KQ Bio (688526) with a target price based on the last closing price of 16.15 [1] Core Insights - The company's net profit margin continues to improve, with a focus on the upcoming new product launches [1][5] - For the first three quarters of 2025, the company achieved a revenue of 738 million yuan, a year-on-year increase of 10.87%, and a net profit of 338 million yuan, a year-on-year increase of 29.62% [4][5] - The third quarter of 2025 saw a revenue of 251 million yuan, a year-on-year decrease of 5.44%, but a net profit increase of 9.17% to 118 million yuan [4][5] Financial Performance - The gross margin for the first three quarters of 2025 was 66.96%, an increase of 2.95% year-on-year, while the net margin was 45.62%, up by 6.55% year-on-year [5] - The company has increased its R&D investment, spending 71.87 million yuan in the first three quarters of 2025, which is 9.74% of its revenue, marking a 17.5% year-on-year increase [5] - The company has received several new veterinary drug registration certificates, indicating ongoing product development and potential for long-term growth [5] Earnings Forecast and Valuation - The company is expected to achieve revenues of 1.13 billion yuan, 1.41 billion yuan, and 1.68 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 460 million yuan, 618 million yuan, and 741 million yuan [6][7] - The projected price-to-earnings (PE) ratios for 2025, 2026, and 2027 are 17.55, 13.06, and 10.89 respectively, supporting the "Buy" rating [6][7]

证券日报网讯 9月29日晚间，科前生物发布公告称，根据《兽药管理条例》和《兽药注册办法》规定， 经中华人民共和国农业农村部审查，批准公司申报的猪塞内卡病毒病灭活疫苗（HB16株，悬浮培养） 为新兽药，并核发《新兽药注册证书》。 （编辑 任世碧） ...

格隆汇9月29日丨科前生物(688526.SH)公布，根据《兽药管理条例》和《兽药注册办法》规定，经中华 人民共和国农业农村部审查，批准公司申报的猪塞内卡病毒病灭活疫苗（HB16株，悬浮培养）为新兽 药，并核发《新兽药注册证书》，作用与用途：用于预防猪塞内卡病毒病。免疫产生期为二免后21日； 免疫期为6个月。 ...

Core Viewpoint - The company, Keqian Bio (688526), has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its inactivated vaccine against Porcine Seneca Valley Virus (HB16 strain) as a new veterinary drug [1] Group 1 - The approval is in accordance with the "Veterinary Drug Management Regulations" and the "Veterinary Drug Registration Measures" [1] - The company has been issued a "New Veterinary Drug Registration Certificate" for the vaccine [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][8]. Core Insights - The company's main business continues to show strong growth, with a focus on building a comprehensive pet ecosystem [2][5]. - In the first half of 2025, the company achieved operating revenue of 1.708 billion yuan, a year-on-year increase of 20.53%, and a net profit attributable to the parent company of 257 million yuan, up 57.59% year-on-year [4][5]. - The company is expanding its market share in the economic animal health sector by focusing on large clients, with significant revenue growth in various product categories [5]. - The company has made substantial progress in its R&D efforts, with a total R&D investment of 114 million yuan in the first half of 2025, accounting for 6.67% of operating revenue [5]. - The company is actively enhancing its pet medical ecosystem, achieving over 40% year-on-year growth in self-owned product supply chain shipments [5]. Summary by Relevant Sections Financial Performance - In Q2 2025, the company reported operating revenue of 886 million yuan, a year-on-year increase of 21.02%, and a net profit of 141 million yuan, up 93.89% year-on-year [4][5]. - The revenue from poultry biological products reached 611 million yuan, a year-on-year increase of 24.71%, while livestock biological products saw a remarkable growth of 110.55% [5]. Revenue and Profit Forecast - The revenue projections for 2025-2027 are adjusted to 3.635 billion, 4.175 billion, and 4.649 billion yuan, representing year-on-year growth rates of 18.39%, 14.88%, and 11.35% respectively [6][7]. - The net profit attributable to the parent company is forecasted to be 459 million, 551 million, and 629 million yuan for the same period [6][7]. Valuation Metrics - The current price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are projected to be 22.75, 18.95, and 16.62 respectively [7][8]. - The return on equity (ROE) is expected to improve from 10% in 2025 to 12% in 2027 [7][8].